Immunomodulatory treatment in multiple sclerosis: Experience at a Brazilian center with 390 patients

Arquivos de Neuro-Psiquiatria

Volumn 64, Issue 1, 2006, Pages 51-54

  Tilbery, Charles Peter ^a,b,d   Mendes, Maria Fernanda ^a,b   Santos De Oliveira, Bianca Etelvina ^a,c   Thomaz, Rodrigo Barbosa ^a,c   Kelian, Giorge Ribeiro ^a,b  

^a Central of Attendance of Multiple Sclerosis Treatment (CATEM)   (Brazil)

^b FCMSCSP   (Brazil)

^c CATEM Multiple Sclerosis Care Center   (Brazil)

^d NONE   (Brazil)

Author keywords

Immunomodulatory therapy; Multiple sclerosis; Treatment failure

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; BEHAVIOR; BRAZIL; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; FEMALE; HEALTH CENTER; HEALTH SURVEY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT ATTITUDE; RECURRENT DISEASE; REMISSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT WITHDRAWAL;

EID: 33646441154     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2006000100011     Document Type: Article

References (13)

1. Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA and The Brazilian Committee for Treatment and Research in Multiple Sclerosis, BCTRIMS. Recomendações para o uso de drogas imunomoduladoras na Esclerose Múltipla. Arq Neuropsiquiatr 2000;58:769-776.
2. Secretaria de Assistência à Saúde, Ministério da Saúde. Portarias no 97 e 98. Diário Oficial da União 23 de março de 2001.
3. Callegaro D, Goldbaum M, Morais L, et al. The prevalence of multiple sclerosis in the city of São Paulo, Brasil. Acta Neurol Scand 2001;104:208-213.
4. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552.
5. Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003;10:671-676.
6. Lubling FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of a international survey. Neurology 1996;46:907-911.
7. Dhib-Jalbut S. Mechanism of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002;58(Suppl 4):S3-S9.
8. Rourke A, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis 2005;11:46-50.
9. Tremlett H, Oger J. Interrupted therapy: stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61:551-554.
10. Freedman MS, Blumhardt LD, Brochet B, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Multiple Sclerosis 2002;8:19-23.
11. Prieto JM, Lenna M. Interferon β en la esclerosis múltiple. Neurology. 2003;36:980-990.
12. Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnostic of multiple sclerosis. Ann Neurol 2001;50:121-127.